Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James S Wilmott

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Pigment Cell & Melanoma Research|June 4, 2014
A light shines on melanoma metastagenesisRicardo Vilain, James S Wilmott, Richard A Scolyer
Surgical Pathology Clinics|May 23, 2021
Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and ManagementRobert V Rawson, James S Wilmott, Richard A Scolyer
Pathology|March 30, 2016
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologistsHojabr Kakavand, James S Wilmott, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pathology|August 31, 2011
The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancersJames S Wilmott, Xu Dong Zhang, Peter Hersey, et al.
Oncoimmunology|November 29, 2012
Combined targeted therapy and immunotherapy in the treatment of advanced melanomaJames S Wilmott, Richard A Scolyer, Georgina V Long, et al.
Melanoma Management|September 8, 2018
Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?James S Wilmott, Peter Hersey, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2017
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic MelanomaTuba N Gide, James S Wilmott, Richard A Scolyer, et al.
Experimental Dermatology|January 17, 2021
Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscapeIsmael A Vergara, James S Wilmott, Georgina V Long, et al.
Melanoma Management|September 8, 2018
Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome ProjectJames S Wilmott, Nicholas K Hayward, Graham J Mann, et al.
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Pigment Cell & Melanoma Research|June 4, 2014
A light shines on melanoma metastagenesisRicardo Vilain, James S Wilmott, Richard A Scolyer
Surgical Pathology Clinics|May 23, 2021
Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and ManagementRobert V Rawson, James S Wilmott, Richard A Scolyer
Pathology|March 30, 2016
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologistsHojabr Kakavand, James S Wilmott, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pathology|August 31, 2011
The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancersJames S Wilmott, Xu Dong Zhang, Peter Hersey, et al.
Oncoimmunology|November 29, 2012
Combined targeted therapy and immunotherapy in the treatment of advanced melanomaJames S Wilmott, Richard A Scolyer, Georgina V Long, et al.
Melanoma Management|September 8, 2018
Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?James S Wilmott, Peter Hersey, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2017
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic MelanomaTuba N Gide, James S Wilmott, Richard A Scolyer, et al.
Experimental Dermatology|January 17, 2021
Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscapeIsmael A Vergara, James S Wilmott, Georgina V Long, et al.
Melanoma Management|September 8, 2018
Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome ProjectJames S Wilmott, Nicholas K Hayward, Graham J Mann, et al.
Pageof 16